Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic tools

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-04-22 DOI:10.1016/j.jhep.2025.04.024

Fredrik Åberg, Juho V. Asteljoki, Panu K. Luukkonen

{"title":"Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic tools","authors":"Fredrik Åberg, Juho V. Asteljoki, Panu K. Luukkonen","doi":"10.1016/j.jhep.2025.04.024","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>FÅ; is the lead author and the guarantor. All authors contributed to study conceptualization. FÅ; did the formal analyses and wrote the first draft. All authors reviewed, critically revised, and approved the final manuscript.</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>Data from the UK Biobank are available for researchers through application (<span><span>https://www.ukbiobank.ac.uk/</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>)</section></section><section><section><h2>Financial support</h2>Dr. Åberg was supported by the Academy of Finland (#338544), Sigrid Jusélius Foundation, Wilhelm and Else Stockmann Foundation, Finska Läkaresällskapet, and Medicinska Understödsföreningen Liv och Hälsa. Dr. Luukkonen was supported by the Academy of Finland (350545), Sigrid Jusélius Foundation, Novo Nordisk Foundation (NNF22OC0074397), Emil Aaltonen Foundation, Finnish Medical Foundation, Wilhelm and Else Stockmann Foundation, Early Career Investigator fund of the University of Helsinki, and</section></section><section><section><h2>Declaration of Competing Interest</h2>FÅ declares consulting fees from Boehringer-Ingelheim, Takeda, Astra Zeneca, and Ipsen; payment for lectures from Abbvie, Sandoz, Siemens Healthineers, Astellas and Norgine; all outside the current work. PKL declares consulting fees from AstraZeneca, Boehringer-Ingelheim, and Bluejay Therapeutics; payment for lectures from Johnson & Johnson, Novartis, and Sandoz; all outside the current work. JVA declares no competing interests.Please refer to the accompanying ICMJE disclosure forms for further</section></section><section><section><h2>Acknowledgments</h2>This study was conducted using the UK Biobank Resource (application number 62797). Copyright © (2023), NHS England. Re-used with the permission of the NHS England and UK Biobank. All rights reserved. This work uses data provided by patients and collected by the NHS as part of their care and support. This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.04.024","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Authors' contributions

FÅ; is the lead author and the guarantor. All authors contributed to study conceptualization. FÅ; did the formal analyses and wrote the first draft. All authors reviewed, critically revised, and approved the final manuscript.

Data availability statement (delete if not applicable)

Data from the UK Biobank are available for researchers through application (https://www.ukbiobank.ac.uk/)

Financial support

Dr. Åberg was supported by the Academy of Finland (#338544), Sigrid Jusélius Foundation, Wilhelm and Else Stockmann Foundation, Finska Läkaresällskapet, and Medicinska Understödsföreningen Liv och Hälsa. Dr. Luukkonen was supported by the Academy of Finland (350545), Sigrid Jusélius Foundation, Novo Nordisk Foundation (NNF22OC0074397), Emil Aaltonen Foundation, Finnish Medical Foundation, Wilhelm and Else Stockmann Foundation, Early Career Investigator fund of the University of Helsinki, and

Declaration of Competing Interest

FÅ declares consulting fees from Boehringer-Ingelheim, Takeda, Astra Zeneca, and Ipsen; payment for lectures from Abbvie, Sandoz, Siemens Healthineers, Astellas and Norgine; all outside the current work. PKL declares consulting fees from AstraZeneca, Boehringer-Ingelheim, and Bluejay Therapeutics; payment for lectures from Johnson & Johnson, Novartis, and Sandoz; all outside the current work. JVA declares no competing interests.Please refer to the accompanying ICMJE disclosure forms for further

Acknowledgments

This study was conducted using the UK Biobank Resource (application number 62797). Copyright © (2023), NHS England. Re-used with the permission of the NHS England and UK Biobank. All rights reserved. This work uses data provided by patients and collected by the NHS as part of their care and support. This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for

查看原文本刊更多论文

SLD 纤维化以外的风险分层：生活方式反应预后工具的案例

章节片段作者贡献FÅ;为第一作者和担保人。所有作者都参与了研究构思。FÅ;进行了正式分析并撰写了初稿。所有作者都审阅、严格修改并批准了最终手稿。数据可用性声明（如不适用请删除）研究人员可通过申请获得英国生物库的数据（https://www.ukbiobank.ac.uk/）财务支持Åberg博士得到了芬兰科学院（#338544）、Sigrid Jusélius基金会、Wilhelm and Else Stockmann基金会、Finska Läkaresällskapet和Medicinska Understödsföreningen Liv och Hälsa的支持。Dr.Luukkonen 博士得到了芬兰科学院 (350545)、Sigrid Jusélius 基金会、诺和诺德基金会 (NNF22OC0074397)、Emil Aaltonen 基金会、芬兰医学基金会、Wilhelm and Else Stockmann 基金会、赫尔辛基大学早期职业研究者基金和竞争利益声明 FÅ 申报了勃林格殷格翰公司、武田制药、阿斯利康和益普生公司的咨询费；从 Abbvie、Sandoz、Siemens Healthineers、Astellas 和 Norgine 获得讲课费；所有这些都不在当前工作范围内。PKL 申报了阿斯利康、勃林格殷格翰和 Bluejay Therapeutics 的咨询费；强生、诺华和山德士的讲课费；所有这些都不在当前工作范围内。致谢本研究使用英国生物库资源（申请号 62797）进行。版权所有©（2023 年），英国国家医疗服务体系。经英国国家医疗服务体系和英国生物库许可后再次使用。保留所有权利。本研究使用了患者提供的数据，这些数据由英国国家医疗服务体系收集，作为其护理和支持的一部分。本研究使用了国家安全避难所提供的数据资产，这些数据资产是 "数据与连接性国家核心研究 "的一部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.